ArticleCureus2026
Gestational Trophoblastic Neoplasm Favouring Epithelioid Trophoblastic Tumour.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelioid trophoblastic tumour (ETT) is a rare form of gestational trophoblastic disease (GTD). We report a case of a 28-year-old woman presenting with abnormal uterine bleeding and mildly elevated serum beta human chorionic gonadotropin (β-hCG) levels. Imaging revealed a heterogeneous uterine mass with lymphadenopathy and pulmonary metastases. Core biopsy histology suggested ETT, but definitive subclassification was limited by small sample size and an ambiguous immunohistochemical profile, which is itself a recognised source of diagnostic uncertainty in this entity. The patient received neoadjuvant platinum-based chemotherapy, followed by total hysterectomy with bilateral salpingo-oophorectomy and lymphadenectomy. At 10 months postoperatively, the patient remains disease-free with normalisation of β-hCG levels. This case illustrates the diagnostic challenges inherent to GTD, particularly the overlap between ETT, placental site trophoblastic tumour (PSTT) and choriocarcinoma; emphasises the importance of integrating multimodal imaging with histopathology within a multidisciplinary team; and demonstrates that a combined approach of chemotherapy and surgical resection can lead to favourable outcomes in this rare entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.